Contribution: Industrial Research Assistance Program – Contributions to Firms
NexPlasmaGen Incorporée
$50,000.00
Validation of a unique High Precision Cold Plasma Device as adjuvant for breast cancer radiotherapy
FY 2018-19 · 2018-04-02
Summary
This project assesses a unique device as a potential adjuvant for breast cancer radiotherapy to enhance the selective kill of breast cancer cells in order to reduce cancer recurrence.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
819165614
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-04-02 | 2018-19 | $50,000.00 |
| 1 | 2018-04-02 | 2018-19 | $50,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 57 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 57 jours.
Agreement End Date
2019-03-29
Agreement Number
905621
Agreement Start Date
2018-04-02
Agreement Title
Validation of a unique High Precision Cold Plasma Device as adjuvant for breast cancer radiotherapy
Agreement Title (French)
Validation d'un dispositif unique plasma froid à haute précision comme adjuvant pour la radiothérapie du cancer du sein
Agreement Type
Contribution
Agreement Value
$50,000.00
Amendment Date
2019-01-31
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project assesses a unique device as a potential adjuvant for breast cancer radiotherapy to enhance the selective kill of breast cancer cells in order to reduce cancer recurrence.
Description (French)
Ce projet évalue un dispositif unique comme adjuvant potentiel pour la radiothérapie du cancer du sein afin d'améliorer la tuerie sélective des cellules du cancer du sein afin de réduire le risque que le cancer se reproduise.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Notre-Dame-de-Grâce--Westmount
Federal Riding (French)
Notre-Dame-de-Grâce--Westmount
Federal Riding Number
24053
NAICS Code
339110
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
819165614
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
NexPlasmaGen Incorporée
Recipient Postal Code
H4A 2T7
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2018-2019-Q1-905621
